Oxford BioMedica (LSE:OXB), a leading gene therapy company, announced today that it has received a Notice of Allowance from the US Patent Office for a key patent application, which significantly extends the protection of ProSavin, the Company’s lead product candidate for Parkinson’s disease. It is expected that the patent will be issued during 2006. This patent describes the genetic composition of ProSavin, and as such is an important addition to the portfolio of patents that protect the product
